Floatz logo

RETINOL

Mycobacterium Tuberculosis

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mycobacterium Tuberculosis cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Texas Tech University Health Sciences Center
Phase 4BB
Trimethoprim
Texas Tech University Health Sciences Center
Phase 4BB
ETHAMBUTOL
Texas Tech University Health Sciences Center
Phase 4BB
Dapsone
Texas Tech University Health Sciences Center
Phase 4BB
Selenium
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3BB

View all 13 →

Same molecule, other indications

RETINOL is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
65 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative ·
57 / 100
View asset →
vitamin A deficiencyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →